Enhancing the Diagnostic Accuracy of Amyloid PET: The Impact of MR-Guided PET Reconstruction.

F-Florbetaben (FBB) uptake in the supratentorial cortex is indicative of amyloid positivity. Due to PET's low spatial resolution, image noise, and spill-over of signal from adjacent white-matter into gray-matter, there are inconsistencies in ratings among trained readers. A set of 264 F-Florbetaben (amyloid) PET/MRI exams were reconstructed using conventional ordered subset expectation maximization (OSEM) method and MR-guided block sequential regularized expectation maximization (MRgBSREM) method.

F-PI-2620 Tau PET is associated with cognitive and motor impairment in Lewy body disease.

Co-pathology is frequent in Lewy body disease, which includes clinical diagnoses of both Parkinson's disease and dementia with Lewy bodies. Measuring concomitant pathology can improve clinical and research diagnoses and prediction of cognitive trajectories. Tau PET imaging may serve a dual role in Lewy body disease by measuring cortical tau aggregation as well as assessing dopaminergic loss attributed to binding to neuromelanin within substantia nigra.

Plasma Aβ/Aβ is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum.

Introduction: The availability of amyloid beta (Aβ) targeting therapies for Alzheimer's disease (AD) is increasing the demand for scalable biomarkers that are sensitive to early cerebral Aβ accumulation.

Methods: We evaluated fully-automated Lumipulse plasma Aβ/Aβ immunoassays for detecting cerebral Aβ in 457 clinically unimpaired (CU) and clinically impaired (CI) Stanford Alzheimer's Disease Research Center (Stanford ADRC) participants and 186 CU in the Stanford Aging and Memory Study (SAMS). Longitudinal change in ADRC plasma Aβ/Aβ and cognition and cross-sectional associations with SAMS memory and tau positron emission tomography (PET) were examined.

The Challenge of External Generalisability: Insights from the Bicentric Validation of a [Ga]Ga-PSMA-11 PET Based Radiomics Signature for Primary Prostate Cancer Characterisation Using Histopathology as Reference.

: PSMA PET radiomics is a promising tool for primary prostate cancer (PCa) characterisation. However, small single-centre studies and lack of external validation hinder definitive conclusions on the potential of PSMA PET radiomics in the initial workup of PCa. We aimed to validate a radiomics signature in a larger internal cohort and in an external cohort from a separate centre.